NeoGenomics, Inc. (NASDAQ:NEO) presented its first quarter 2025 financial results on April 29, 2025, showcasing a strong performance that marks a significant improvement following disappointing Q4 ...
InvestorsHub on MSN
NeoGenomics slides more than 5% despite fourth-quarter earnings beat
NeoGenomics Inc (NASDAQ:NEO) on Tuesday posted fourth-quarter results that topped Wall Street estimates, though shares declined sharply in early trading as investors weighed the company’s growth ...
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026 NeoGenomics, Inc. misses on earnings ...
NeoGenomics Inc . (NASDAQ:NEO) presented its second quarter 2025 financial results on July 29, revealing mixed performance that prompted a significant market reaction. The oncology diagnostics company ...
NeoGenomics reported Q4 2025 revenue of $190 million, representing an 11% year-over-year increase, slightly above analyst expectations of $188.14 million. The company achieved its tenth consecutive ...
FORT MYERS, Fla., December 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...
Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results